Nothing Special   »   [go: up one dir, main page]

EA201591175A1 - Трициклические соединения в качестве ингибиторов cftr - Google Patents

Трициклические соединения в качестве ингибиторов cftr

Info

Publication number
EA201591175A1
EA201591175A1 EA201591175A EA201591175A EA201591175A1 EA 201591175 A1 EA201591175 A1 EA 201591175A1 EA 201591175 A EA201591175 A EA 201591175A EA 201591175 A EA201591175 A EA 201591175A EA 201591175 A1 EA201591175 A1 EA 201591175A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tricyclic compounds
cftr inhibitors
provides
cftr
inhibitors
Prior art date
Application number
EA201591175A
Other languages
English (en)
Inventor
Махбуб Ахмед
Александер Эшалл-Келли
Грэм Чарльз Блумфилд
Луиза Гюэриц
Джеффри МакКенна
Джозеф Маккенна
Саймон Маттон
Ракеш Пармар
Джон Шеферд
Пол Райт
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201591175A1 publication Critical patent/EA201591175A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение предоставляет ингибитор CFTR формулы (I) или его фармацевтически приемлемую соль и его терапевтические применения, например, при лечении диареи. Изобретение также предоставляет комбинацию фармакологически активных агентов и фармацевтическую композицию.
EA201591175A 2012-12-19 2013-12-17 Трициклические соединения в качестве ингибиторов cftr EA201591175A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739337P 2012-12-19 2012-12-19
US201361906154P 2013-11-19 2013-11-19
PCT/IB2013/061041 WO2014097147A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds as cftr inhibitors

Publications (1)

Publication Number Publication Date
EA201591175A1 true EA201591175A1 (ru) 2015-11-30

Family

ID=50030371

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591175A EA201591175A1 (ru) 2012-12-19 2013-12-17 Трициклические соединения в качестве ингибиторов cftr

Country Status (15)

Country Link
US (1) US9303035B2 (ru)
EP (1) EP2935277B1 (ru)
JP (1) JP6284545B2 (ru)
KR (1) KR20150095925A (ru)
CN (1) CN105008370B (ru)
AR (1) AR094123A1 (ru)
AU (1) AU2013365827A1 (ru)
BR (1) BR112015014433A2 (ru)
CA (1) CA2895656A1 (ru)
EA (1) EA201591175A1 (ru)
ES (1) ES2650372T3 (ru)
MX (1) MX2015007940A (ru)
TW (1) TW201429976A (ru)
UY (1) UY35209A (ru)
WO (1) WO2014097147A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2730855C2 (ru) * 2015-12-24 2020-08-26 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
AU2013365739A1 (en) 2012-12-19 2015-07-09 Novartis Ag Tricyclic compounds for inhibiting the CFTR channel
EA201591175A1 (ru) 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения в качестве ингибиторов cftr
CN115710233A (zh) 2015-12-24 2023-02-24 加利福尼亚大学董事会 Cftr调节剂及其使用方法
CA3073718A1 (en) 2017-08-24 2019-02-28 The Regents Of The University Of California Ocular pharmaceutical compositions
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
BR112023022315A2 (pt) 2021-04-29 2024-02-20 Novartis Ag Quimeras direcionadas à desubiquitinase e métodos relacionados

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224974B (ru) * 1991-07-02 1994-06-11 Hoffmann La Roche
US6608098B1 (en) 1999-08-25 2003-08-19 Banyu Pharmaceutical Co., Ltd. Isoindole derivatives
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CN101668751A (zh) 2006-12-12 2010-03-10 先灵公司 天冬氨酰蛋白酶抑制剂
US20110015137A1 (en) * 2007-07-05 2011-01-20 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8609661B2 (en) * 2009-08-10 2013-12-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9062073B2 (en) * 2011-05-27 2015-06-23 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
AU2013365739A1 (en) 2012-12-19 2015-07-09 Novartis Ag Tricyclic compounds for inhibiting the CFTR channel
EA201591175A1 (ru) 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения в качестве ингибиторов cftr

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2730855C2 (ru) * 2015-12-24 2020-08-26 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
US11084795B2 (en) 2015-12-24 2021-08-10 The Regents Of The University Of California CFTR regulators and methods of use thereof

Also Published As

Publication number Publication date
KR20150095925A (ko) 2015-08-21
ES2650372T3 (es) 2018-01-18
EP2935277A1 (en) 2015-10-28
BR112015014433A2 (pt) 2017-07-11
WO2014097147A1 (en) 2014-06-26
EP2935277B1 (en) 2017-08-30
AR094123A1 (es) 2015-07-08
CN105008370A (zh) 2015-10-28
MX2015007940A (es) 2016-03-11
UY35209A (es) 2014-07-31
TW201429976A (zh) 2014-08-01
CN105008370B (zh) 2017-06-09
AU2013365827A1 (en) 2015-07-09
JP6284545B2 (ja) 2018-02-28
US9303035B2 (en) 2016-04-05
CA2895656A1 (en) 2014-06-26
JP2016507498A (ja) 2016-03-10
US20140171412A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
IN2015DN00185A (ru)
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
PH12015501386A1 (en) Tricyclic compounds
EA201692298A1 (ru) Производные карбоксамидов
EA201391524A1 (ru) Производные гликозида и их применение
TN2014000060A1 (en) Benzothiazolone compound
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
MX2016013561A (es) Activadores de herg policiclicos.
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
EA201300160A1 (ru) 2,3,5-тризамещенные тиофены и их применение
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch